The biopharmaceutical industry has been transformed by the adoption of new technologies and solutions. Changes such as digitizing operations through automation and robotics have improved product quality and improving efficiency. These new methods have also allowed for opportunities to meet the needs of smaller patient populations. With these new changes, it can be difficult for suppliers to plan for the level of demand expected from the industry during this rapid growth phase.
In addition, the COVID-19 pandemic has caused strains on supply chains, delays in production, and staff shortages, which means delays related to raw material and finished goods production. Before COVID, customer base level forecasts of demand were low, even with substantial resources and efforts dedicated to forecasting demand levels across their portfolio. Since manufacturing requirements and volumes are based on the level of customer demand, inaccurate forecasting levels can lead to vulnerabilities.
Learn more about Cytiva’s approach to supply risk management and tips on anticipating demand and accurate demand planning.